Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Megan C Herink

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Pharmacotherapy|July 26, 2017
Eteplirsen for the Treatment of Duchenne Muscular Dystrophy: Quality of Evidence Concerns-an Alternative ViewpointAdriane N Irwin, Megan C Herink
Pharmacotherapy|July 26, 2018
FDA Breakthrough Therapy Designation: Evaluating the Quality of the Evidence behind the Drug ApprovalsMegan C Herink, Adriane N Irwin, Gregory M Zumach
Current Neurology and Neuroscience Reports|July 31, 2023
Polypharmacy in Multiple Sclerosis: Prevalence, Risks, and Mitigation StrategiesW Daniel Chapman, Megan C Herink, Michelle H Cameron, et al.
Journal of Managed Care & Specialty Pharmacy|June 29, 2021
Effect of relaxing hepatitis C treatment restrictions on direct-acting antiviral use in a Medicaid program: an interrupted time series analysisMegan C Herink, Jonah Geddes, Kim Vo, et al.
Drugs|August 24, 2019
Clinical Management of Pharmacokinetic Drug Interactions with Direct Oral Anticoagulants (DOACs)Megan C Herink, Yan F Zhuo, Craig D Williams, et al.
Systematic Reviews|April 16, 2015
The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysisAmanda S Meeker, Megan C Herink, Dean G Haxby, et al.
Pharmacy (Basel, Switzerland)|October 26, 2022
Pharmacists' Knowledge and Perceptions of FDA Approval Standards and the Breakthrough Therapy DesignationMegan C Herink, Kirbee Johnston, Kristin Breninger, et al.
The Primary Care Companion for CNS Disorders|July 2, 2024
A 3-Times-Daily Dosing Scheme of Prazosin to Treat Posttraumatic Stress Disorder-Induced Psychological Distress in the HospitalKendall J Tucker, Trisha T Villanueva, Miles Fletcher, et al.
Pharmacotherapy|December 19, 2013
Evidence behind FDA alerts for drugs with adverse cardiovascular effects: implications for clinical practiceDaniel M Rackham, Megan C Herink, Ian G Stevens, et al.
Journal of Pharmacy Practice|March 17, 2023
Adherence to Hepatitis C Treatment Among Underserved Patients With Substance Use Disorder in a Pharmacist-led Treatment ModelAnthony J McKenzie, Brie N Noble, Megan C Herink, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Pharmacotherapy|July 26, 2017
Eteplirsen for the Treatment of Duchenne Muscular Dystrophy: Quality of Evidence Concerns-an Alternative ViewpointAdriane N Irwin, Megan C Herink
Pharmacotherapy|July 26, 2018
FDA Breakthrough Therapy Designation: Evaluating the Quality of the Evidence behind the Drug ApprovalsMegan C Herink, Adriane N Irwin, Gregory M Zumach
Current Neurology and Neuroscience Reports|July 31, 2023
Polypharmacy in Multiple Sclerosis: Prevalence, Risks, and Mitigation StrategiesW Daniel Chapman, Megan C Herink, Michelle H Cameron, et al.
Journal of Managed Care & Specialty Pharmacy|June 29, 2021
Effect of relaxing hepatitis C treatment restrictions on direct-acting antiviral use in a Medicaid program: an interrupted time series analysisMegan C Herink, Jonah Geddes, Kim Vo, et al.
Drugs|August 24, 2019
Clinical Management of Pharmacokinetic Drug Interactions with Direct Oral Anticoagulants (DOACs)Megan C Herink, Yan F Zhuo, Craig D Williams, et al.
Systematic Reviews|April 16, 2015
The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysisAmanda S Meeker, Megan C Herink, Dean G Haxby, et al.
Pharmacy (Basel, Switzerland)|October 26, 2022
Pharmacists' Knowledge and Perceptions of FDA Approval Standards and the Breakthrough Therapy DesignationMegan C Herink, Kirbee Johnston, Kristin Breninger, et al.
The Primary Care Companion for CNS Disorders|July 2, 2024
A 3-Times-Daily Dosing Scheme of Prazosin to Treat Posttraumatic Stress Disorder-Induced Psychological Distress in the HospitalKendall J Tucker, Trisha T Villanueva, Miles Fletcher, et al.
Pharmacotherapy|December 19, 2013
Evidence behind FDA alerts for drugs with adverse cardiovascular effects: implications for clinical practiceDaniel M Rackham, Megan C Herink, Ian G Stevens, et al.
Journal of Pharmacy Practice|March 17, 2023
Adherence to Hepatitis C Treatment Among Underserved Patients With Substance Use Disorder in a Pharmacist-led Treatment ModelAnthony J McKenzie, Brie N Noble, Megan C Herink, et al.
Pageof 2